Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial
- 1 October 2012
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (10) , 2466-2469
Abstract
No abstract availableKeywords
Funding Information
- Amgen
This publication has 9 references indexed in Scilit:
- Recent advances in the IL-17 cytokine familyCurrent Opinion in Immunology, 2011
- Anti-cytokine therapies for psoriasisExperimental Cell Research, 2011
- Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in PsoriasisJournal of Investigative Dermatology, 2011
- Functional Specialization of Interleukin-17 Family MembersImmunity, 2011
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and UveitisScience Translational Medicine, 2010
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJournal of Allergy and Clinical Immunology, 2009
- Structure and signalling in the IL-17 receptor familyNature Reviews Immunology, 2009
- The IL-23/Th17 Axis in the Immunopathogenesis of PsoriasisJournal of Investigative Dermatology, 2009
- Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skinBritish Journal of Dermatology, 2009